One of the commitments of the NICR is to use national and European research infrastructures to advance cancer research, diagnosis, and treatment. Institutions involved in the NICR are themselves directly involved in the management of large research infrastructures and synergies between the participating NICR teams make it possible to create added value, avoid duplication, and increase research efficiency. NICR actively collaborates with several large research infrastructures in order to enhance its cancer research capabilities. These partnerships provide NICR with access to advanced technologies and resources, thus facilitating cutting-edge research and innovation.
Key Collaborations:
- EATRIS-ERIC and EATRIS-CZ: NICR uses the European and national infrastructure for translational medicine, EATRIS-ERIC and EATRIS-CZ, in order to bridge the gap between laboratory discoveries and clinical applications. This infrastructure is essential in guiding the preclinical and early clinical development of promising medicinal products ranging from small molecules and radiopharmaceutics all the way to in vitro diagnostics and software applications.
- BBMRI-ERIC and BBMRI.CZ: Through the European and national repository of biological samples, BBMRI-ERIC and BBMRI.CZ, NICR can access a vast collection of biological materials essential for cancer research.
- ECRIN and CZECRIN: Collaboration with the European and national infrastructure for clinical research, ECRIN and CZECRIN, enables NICR to conduct multi-centre clinical trials and studies, thus enhancing the robustness of its research findings.
- ISBE and C4SYS: By partnering with the European and national infrastructure for systems biology, ISBE and C4SYS, NICR integrates complex biological data in order to better understand the mechanisms of cancer.
- EU-OPENSCREEN and CZ-OPENSCREEN: NICR collaborates with the European and national infrastructure for chemical biology, EU-OPENSCREEN and CZ-OPENSCREEN, to identify and develop new chemical compounds that have potential therapeutic effects against cancer. This includes the screening of targeted or drug-repurposing libraries as well as of novel proprietary compounds.
- Euro-BioImaging and Czech-BioImaging: Through the European and national infrastructure for biological and biomedical imaging, Euro-BioImaging and Czech-BioImaging, NICR can access state-of-the-art imaging technologies crucial for visualising cancer at both a cellular and molecular level.
- ELIXIR and ELIXIR CZ: Collaboration with the European and national infrastructure for life science data, ELIXIR and ELIXIR CZ, allows NICR to manage and analyse large datasets, thus facilitating bioinformatics research in oncology.
- INFRAFRONTIER and Czech Centre for Phenogenomics: By partnering with the European and national infrastructure for functional genomics of mouse models, INFRAFRONTIER and the Czech Centre for Phenogenomics, NICR can study the genetic factors relevant to cancer using advanced animal models.
- Instruct-ERIC and Czech Infrastructure for Integrative Structural Biology: Through collaboration with the European and national infrastructure for structural biology, Instruct-ERIC and the Czech Infrastructure for Integrative Structural Biology, NICR can investigate the three-dimensional structures of cancer-related biomolecules, which helps the participating teams in drug design and development.
- National Centre for Medical Genomics: NICR collaborates with the National Centre for Medical Genomics to explore the genetic variations associated with cancer. This aids the development of personalised medicine.
These collaborations exemplify NICR's commitment to using both national and European research infrastructures to advance cancer research, diagnostics, and treatment.